Annovis Bio Inc ANVS shares are trading higher by 180% at $74 Friday morning after the company announced results from its double-blind placebo-controlled study of ANVS401, showing statistically significant cognitive improvement as measured by the ADAS-Cog11.
See Also: Annovis Bio's Alzheimer's/Parkinson's Candidate Shows Cognitive Improvement
Annovis Bio is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
